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Abstract
We present a cell based system and experimental approach to characterize agonist and antagonist selectivity for ligand-
gated ion channels (LGIC) by developing sensor cells stably expressing a Ca
2+ permeable LGIC and a genetically encoded
Fo ¨rster (or fluorescence) resonance energy transfer (FRET)-based calcium sensor. In particular, we describe separate lines
with human a7 and human a4b2 nicotinic acetylcholine receptors, mouse 5-HT3A serotonin receptors and a chimera of
human a7/mouse 5-HT3A receptors. Complete concentration-response curves for agonists and Schild plots of antagonists
were generated from these sensors and the results validate known pharmacology of the receptors tested. Concentration-
response relations can be generated from either the initial rate or maximal amplitudes of FRET-signal. Although assaying at
a medium throughput level, this pharmacological fluorescence detection technique employs a clonal line for stability and
has versatility for screening laboratory generated congeners as agonists or antagonists on multiple subtypes of ligand-
gated ion channels. The clonal sensor lines are also compatible with in vivo usage to measure indirectly receptor activation
by endogenous neurotransmitters.
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Introduction
Nicotinic acetylcholine receptors (nAChRs) are pentameric
ligand-gated ion channels (LGIC) belonging to the sub-family of
Cys-loop receptors. They are found in the central and peripheral
nervous systems of both vertebrate and invertebrate species.
Specific nAChR subtypes are recognized pharmaceutical targets
for many central nervous system (CNS) diseases and conditions
[1]. For example: the a7-nAChR is targeted for schizophrenia [2],
Alzheimer’s disease [3], and cognition enhancement [4], and the
a4b2-nAChR is also targeted for Alzheimer’s disease [5,6], and for
tobacco addiction [7,8]. Therefore, a particular challenge in
therapeutic considerations is achieving subtype selectivity among
the nAChRs. Sorting out the desirable actions within the subunit
diversity of the nAChR family from the largely unwanted
responses, via off-target receptors, is an important facet of the
therapeutic approach [9].
For selection of pharmacologic leads, a facilitated and rapid
assay of nAChR subtype selective agents is required early on in the
screening process [10]. While electrophysiological methods
through whole cell recording and patch clamp analysis can
subsequently be used to uncover mechanism, they lack the
scalability, cost reduction and automation that can be attained
through the use of photon generated signals from multi-well plates
[11,12]. The scalability and automation derived from fluorometric
imaging plate readers (FLIPR) have encouraged the use of
fluorescence-based dyes in screening therapeutics on nAChRs
[13,14]. Yet conventional fluorescent dyes to detect depolarization
or intracellular calcium, are limited by cost, variations in dye
administration, dye shelf life, and cell perturbations during
injection. Hence a stable, clonal cell line containing a light
detection sensor and a receptor, which is generated from
incorporating the respective genetic material, become critical
considerations in developing a medium throughput assay for
selective receptor activation. Bioluminescent Ca
2+ reporters, such
as GFP-aequorin, have been shown to be an applicable method in
creating cell lines that contain a genetically encoded light detection
method [15,16]. Although bioluminescent reporters address the
issues of variations in dye administration, shelf life, and cost; they
are still susceptible to cell perturbations during injection,
interference from fluorescent ligands, and are limited in time
resolution due to the length of their decay. Applications that take
advantage of fusing fluorescent protein Fo ¨rster (or fluorescence)
resonance energy transfer (FRET) pairs with Ca
2+ binding
proteins, such that changes in intracellular Ca
2+ levels can be
visualized through a combination of donor quenching and
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enabling investigators to monitor signal transduction pathways in
varying cells [17]. The use of FRET pairs over Ca
2+ sensing
bioluminescent reporters minimizes the perturbations of ligand
fluorescence and cell perturbation by solvent during the injection
phase. Although many genetically encoded Ca
2+ sensors exist
[18,19], the development of the Ca
2+ sensor TN-XXL allowed for
a highly sensitive and effective FRET based sensor [20]. Its
incorporation with over-expressed G-protein-coupled receptors
(GPCR) to produce cell-based neurotransmitter fluorescent
engineered reporters (CNiFERs) offered the potential to overcome
most of the limitations of the Ca
2+ bioluminescent reporters [21].
In our previous studies, the generation of a genetically encoded
sensitive Ca
2+ sensor with a stably over-expressed GPCR allowed
for in vivo validation of a compound’s activity in situ in brain [21].
High-throughput fluorescence methodology [14], which has been
previously utilized, affords a dual application to the stable, clonal
cell line sensors we generated for transplanted cells. Here we
report on generating and utilizing nAChR CNiFERs to measure
nAChR activation via Ca
2+ flux through ion channels in the cell
membrane as opposed to GPCR mediated release primarily from
intracellular stores described previously (Figure 1). Our studies
extend the application of CNiFERs to prevalent and targeted CNS
nAChR subtypes, the a7 and a4b2, and also the 5-HT3A serotonin
receptor. A chimaeric receptor CNiFER composed of a7/5-HT3A
was also generated to gain additional insight into activation of the
wildtype a7-nAChR. The chimaeric receptor has been shown to
have a desensitization rate comparable to 5-HT3A receptors, and
more recently a higher conducting variant has been created
[22,23,24]. This chimaeric receptor still maintains ligand affinities
for that of the full-length a7-nAChR, which allows for a positive
allosteric modulator (PAM) free study of the a7-nAChR [23]. We
report on a cell-based assay incorporating the use of nAChR
CNiFERs to identify and characterize nAChR agonists and
antagonists with a low cost, medium throughput fluorescence
assay. The system is capable of detection on a monolayer of cells in
a 7 mm diameter well of a 96-well plate and has the potential to be
scaled to a high throughput platform.
Results and Discussion
Cell Based Neurotransmitter Fluorescent Engineered
Reporters (CNiFERs)
The first CNiFERs were developed for applications of
monitoring cortical acetylcholine release in the cerebral cortex
of rats using the M1-CNiFER [21]. The CNiFERs presented here
were developed to facilitate pharmacological screening, potency
rank ordering and characterization of compounds for calcium
permeable ligand-gated ion channels (LGICs), with a particular
focus on the homomeric a7 and heteromeric a4b2 nAChRs. The
5-HT3A serotonergic LGIC receptor exists in its simplest form as
a homopentamer similar to the a7-nAChR [25]. Although the 5-
HT3A receptor has a large calcium conductance, the 5-HT3AB
heteromeric receptors do not and therefore may have limited
applicability with this technique [26]. Since antagonists, such as
tropisetron, for the 5-HT3A receptor are known to activate a7-
nAChRs, 5-HT3A CNiFERs not only expand the neurotransmit-
ter target base, but also become a model system for testing
opposing receptor responses [27]. LGIC agonist responses were
measured with CNiFERs by monitoring TN-XXL FRET ratios,
emissions of citrine cp174 (527 nm) to eCFP (485 nm), over 120
seconds with agonist injections occurring at the 30 second time-
point. Figure 2a is an example of the fluorescent signals generated
from a 5-HT3A CNiFER single concentration response to 3 mM
5-Hydroxytryptamine (5-HT) injected at 30 seconds. FRET
ratios of the emissions for a concentration range of 0.3–3 mM5 -
HT is shown in Figure 2b. Concentration response curves can
then be generated from the peak FRET ratio values for each
concentration.
a7-nAChR CNiFERs
Due to the rapid rate of desensitization of the a7-nAChR in the
time frame of milliseconds [28], monitoring agonist-elicited
fluorescence responses were not possible without including a
PAM [29]. In our case we used the type II PAM, N-(5-Chloro-2,4-
dimethoxyphenyl)-N’-(5-methyl-3-isoxazolyl)-urea (PNU-120596),
and found that concentrations of 10 mM and above incubated on
cells for at least 30 min (data not shown) yielded a maximal
agonist-elicited fluorescence response (Figure 3a). Characteristic of
a type II PAM, PNU-120596 will increase ion flux through the a7-
nAChRs by decreasing its desensitization rate [30]. PNU-120596
likely interacts with a region in the transmembrane helices
spanning TM1, TM2, and TM4 to prevent an activated a7-
nAChR from switching to its desensitized state once activated
[31]. PNU-120596 modulating activity results in an increase in the
number of receptors remaining in an open or activated state.
Accordingly, not only is a larger response produced, but also a
lower concentration of agonist is likely needed to observe a
response. Agonist EC50 values measured with the a7-nAChR
CNiFER in the presence of PNU-120596 are less than those
reported in the literature for a7-nAChR agonists without PNU-
120596, as observed in Table 1. Nevertheless, these considerations
are not likely to affect the rank ordering for agonist potencies.
Assay of antagonists is conducted as a null method and should be
independent of agonist used, provided a single receptor subtype is
being analyzed. When (6)-epibatidine responses from a7-nAChR
CNiFERs were blocked with three concentrations (3, 10, 30 nM)
of methyllycaconitine (MLA) (Figure 3b). Schild analysis of the
parallel concentration versus fluorescence readout showed MLA to
block a7-nAChR CNiFERs competitively with a slope of
21.260.3 and with an observed Ka value of 3.261.4 nM for
the antagonist (Figure 3c, Table 2).
Figure 1. Simplistic representation of LGIC-CNiFERs and their
response. Upon activation of a calcium permeable receptor, Ca
2+
enters the cell and upon binding to TN-XXL produces a conformational
change eliciting a fluorescence change reflected in quenching of the
donor fluorescence and excitation of the acceptor.
doi:10.1371/journal.pone.0016519.g001
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16519Figure 2. Direct FRET measurement of response. A. Measured time-course emission wavelengths for eCFP (485 nm) and Citrine cp174 (527 nm)
on 5-HT3A CNiFERs. 5-HT was injected at 30 s at 3 mM concentration to produce a Ca
2+ influx causing a concentration dependent FRET response from
the TN-XXL reporter. Measurements were taken every 3.52 s with excitation at 436 nm. B. FRET-Ratio (Citrine cp147/eCFP) time-course responses
from 5-HT3A CNiFERs to varying concentrations of 5-HT. Peak values or initial rates may be used to plot a concentration dependent curve to estimate
EC50 values. Peak values were used to generate concentration response curves.
doi:10.1371/journal.pone.0016519.g002
Figure 3. a7-nAChR CNiFER: PNU-120596 activation and methyllycaconitine antagonism. A. Concentration dependent response of PNU-
120596 incubated for 30 minutes on a7-nAChR CNiFERs and stimulated with 0.1 mM( 6)-epibatidine. The response curve shows that concentrations
greater than 10 mM PNU-120596 would produce a maximal response. B. Competitive blockade of (6)-epibatidine elicited responses on a7-nAChR
CNiFERs by MLA. The EC50 values for each curve shifted from 3.6 nM to 17 nM, 29 nM, and 160 nM for 3 nM, 10 nM, 30 nM MLA respectively. C.
Schild plot of concentration dependent shifts. A slope of 21.260.3 confirmed MLA to block competitively.
doi:10.1371/journal.pone.0016519.g003
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The chimaeric a7/5-HT3A receptor does not exhibit the rapid
desensitization rate seen with the wildtype (wt) a7-nAChR and
thus neither requires PNU-120596, nor would PNU-120596 be
effective [31], for achieving sufficient fluorescence signals within
the time frame of the assay. In the presence of PNU-120596,
agonists tend to have approximately a 10-fold higher affinity for
the a7-nAChR (Table 1). The EC50 value for (6)-epibatidine
measured in the presence of PNU-120596 for a7-nAChR
CNiFERs was 28616 nM, whereas the EC50 value measured
without PNU-120596 on a7/5-HT3A CNiFERs was 250650 nM.
In this case the chimaeric a7/5-HT3A receptor can possibly yield
measurements of potency closest to the actual channel opening
event of the compound for the wt a7-nAChR. This difference may
reflect affinity differences between the activatable and desensitized
state of the receptor originally shown in the muscle nAChR [32].
Concentration-response curves generated with (6)-epibatidine on
a7/5-HT3A CNiFERs were blocked with MLA (3, 10, 30 nM) to
characterize MLA antagonism. The resulting shifts were similar to
those seen with the a7-nAChR CNiFERs (Figure 4a). The
decrease in the maximum responses in the presence of MLA
(Figure 4a) was also seen on several occasions with the a7-nAChR
CNiFERs. This suggests a non-competitive component of
antagonism, or that the half time of 2.3 min for dissociation of
MLA is too slow to allow for complete dissociation from the
receptor in the timeframe of our measurements [33]. Schild
analysis showed a slope of 21.860.2, which indicates that MLA is
not solely a competitive antagonist at the a7/5-HT3A CNiFERs
(Figure 4b). However, the major competitive component yielded a
Ka of 2.560.1 nM, a value very close to that measured on the a7-
nAChR CNiFERs (Table 2). The similarity of the antagonist
affinities shows that using a PAM only affects agonist constants
and employing the null method for determining Ka values negates
the effect of PAMs. The similarity of these values for occupation by
the antagonist validates the use of these chimaeric a7/5-HT3A
CNiFERs for characterizing ligands for the a7-nAChR without
the need to use a PAM. Antagonist binding is more apt to be
characterized by a single binding state as shown with the muscle
nAChRs [34].
a4b2-nAChR CNiFERs
To characterize the a4b2-nAChR CNiFERs, concentration-
response relationship data were generated with various concen-
trations of (6)-epibatidine in the absence and presence of a known
competitive antagonist, dihydro-beta-erythroidine (DHbE) (0.3, 1,
3 mM). The resulting concentration-response curves showed a
parallel shift with little decrease in the maximum revealing
competitive antagonism (Figure 5a). Schild analysis confirmed
DHbE acts competitively with a slope of 20.960.1 and measured
aK a value of 136654 nM (Figure 5b, Table 2).
5-HT3A Serotonin CNiFERs
The 5-HT3A receptor was generated from a single transfected
subunit to form a homomeric pentamer. Concentration-response
curves show serotonin to be an agonist, as expected, with an EC50
of 349678 nM (n=16). A near competitive block is achieved with
ondansetron as an antagonist (Figure 6, Table 2). Other setrons,
such as tropisetron and granisetron appear to show a greater non-
competitive component (data not shown), but this observation may
result from slow dissociation of the antagonist during the agonist
Table 1. Comparison of Agonist EC50 using CNiFER and non-CNiFER detection
f.
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a. Measured in aCSF.
b. Measured with Ca
2+ dye (Fluo-3-AM) on HEK293 cells expressing human receptors [23] *(Geometric Mean[-SD=2.4, +SD=5.1])[39].
c. Measured with 10 mM PNU-120596 in aCSF.
d. Measured with potential-sensitive dye against human receptors. *(2a3b) [35].
e. Measured with potential-sensitive dye and 3 mM PNU-120596.
{To be published Kuryatov A, Mukherjee J, and Lindstrom J.
f. Each n is calculated as an EC50 value from an individual concentration-response curve.
doi:10.1371/journal.pone.0016519.t001
Table 2. Comparison of Antagonist Ka from CNiFERs to non-CNiFERs detection
f.
LGIC-CNiFER Antagonist CNiFER Ka, nM Schild Slope IC50,n M
a7-nAChR MLA 3.261.4
a (n=6) 21.260.3 2.961.2
c
a7/5-HT3A MLA 2.560.1
b (n=2) 21.860.2 36613
d
a4b2-nAChR DHbE 136654




b (n=7) 21.360.04 16.065.7(Ki)
e
a. Measured with 10 mM PNU-120596 in aCSF.
b. Measured in aCSF.
c. Measured with potential-sensitive dye (to be published Kuryatov A, Mukherjee J, and Lindstrom J). *(2a3b) [40].
d. Measured with Ca
2+ dye (Fluo-3-AM) on HEK293 cells expressing human receptors [23]. *(Geometric Mean [-SD=66, +SD=109])[39].
e. Measured competition against [
3H]-ICs-205-930 in mouse neuroblastoma-glioma cells (NG-108-15) (5-HT3AB)[41,42].
f. Each n is calculated from a Schild regression plot.
doi:10.1371/journal.pone.0016519.t002
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nAChR.
Concluding Analysis
CNiFER detection of agonist responses and blockade of the
responses by antagonists, originally shown for a GPCR, musca-
rinic M1 receptor, are equally applicable to calcium permeable
ligand-gated ion channels, as shown here for subunits of the Cys-
loop receptor family. The chief advantages stem from the
versatility of the system enabling one to measure responses to a
variety of receptors in the same family by multi-array analysis. By
developing the assay in a clonal cell line in which stable lines were
first generated from the receptor subtype followed by plasmid
transfection, or transduction with a viral vector containing the
recombinant DNA encoded sensor, one can robustly generate
previously established receptor subtype clones containing the
FRET based sensor. These sensor clones may be used for either a
robust medium-throughput assay or for in vivo implantation to
determine neurotransmitter release [21]. The Molecular Devices
FlexStation III instrument allows for multiple well samples in a 96
well plate to be assayed over 30 min plate intervals. This method
could be scaled for use with higher throughput assaying via the
FLIPR, or even for integration with high content screening
platforms. Comparison of LGIC CNiFERs to their non-CNiFER
counterparts shows similar ligand affinities and demonstrates that
the TN-XXL sensor does not affect LGIC dissociation constants
(Table 2). Our demonstration of (6)-epibatidine and 5-HT-elicited
responses with predicted concentration ratio shifts from well
known competitive antagonists provides a characterized cell
system to distinguish defined receptor responses from indirect
actions. We establish the utility of the CNiFER sensor for
characterizing agonist and antagonist parameters for new ligand
candidates on LGIC nicotinic and serotonin systems.
A chief limitation is the slow read time between measurements
and the sensitivity of the sensor, resulting in difficulty with fast
desensitizing receptor systems; yet with the judicious use of agents
that maintain an active state and retard desensitization, this
obstacle may be overcome and a suitable rank ordering of potency
determined for agonists and antagonists. Distortions that might be
achieved with more prolonged measurements of maximal
Figure 4. a7/5-HT3A CNiFER: Methyllycaconitine antagonism. A. Competitive blockade of (6)-epibatidine elicited responses on a7/5-HT3A
CNiFERs by MLA. The EC50 values for each curve shifted from 86 nM to 230 nM, 900 nM, and 8.3 mM for 3 nM, 10 nM, 30 nM MLA respectively. B.
Schild plot of concentration dependent shifts. A slope of 21.860.2 shows MLA to block competitively but with a percentage of receptors still
occupied, attributing to a slight non-competitive component that may be an artifactual result of slow dissociation.
doi:10.1371/journal.pone.0016519.g004
Figure 5. a4b2-nAChR CNiFER: DHbE antagonism. A. Competitive blockade of (6)-epibatidine elicited responses on a4b2-nAChR CNiFERs by
DHbE. The EC50 values for each curve shifted from 8.9 nM to 42 nM, 130 nM, and 270 nM for 300 nM, 1 mM, 3 mMD H bE respectively. B. Schild plot of
concentration dependent shifts. A slope of 20.960.1 confirmed DHbE to block competitively.
doi:10.1371/journal.pone.0016519.g005
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rate of depolarization. The slow off-rate antagonists that reduce
signal and reveal an artifactual non-competitive component to
antagonism exhibit another limitation from the reported on assay.
By analyzing only the competitive aspect of the compound, one
can effectively estimate Ka values. Therefore the use of LGIC
CNiFERs in the development of therapeutics for CNS disorders is
robust and cost-effective.
Methods
Generation of Stable Ca
2+ Sensing nAChR Cell Lines
Individual HEKtsA201human a4b2 nicotinic receptor stable
cell lines were generated as previously described [35]. Briefly
human cDNA clones encoding a4 (pcDNA3.1/Zeo(2)) and b2
(pRc/CMV) nAChR subunits were transfected in equal amounts
into HEKtsA201 cells using the FuGene6 transfection agent
(Roche Diagnostics, Indianapolis, IN). Zeocin (0.5 mg/ml) was
used for selection of a4 expression, and G418 (0.6 mg/ml; both
from Invitrogen, Carlsbad, CA) was used for b2 selection to
produce a stable, clonal cell line. Selection of the HEKtsA201
human a7-Ric3 nicotinic receptor stable cell lines and their
pharmacological properties has been reported by Kuryatov,
Mukherjee, and Lindstrom. The basic approach to preparing
the line was similar to that used for the a4b2-nAChR cell line and
its functional properties were similarly assayed using a potential-
sensitive indicator after treatment with chemical chaperones to
upregulate the amount of AChR. The stable clones were used to
generate individual nAChR CNiFERs. The TN-XXL control
CNiFERs (lacking over-expressed receptors) [20,21], and mouse 5-
HT3A CNiFERs were developed as described in [21]. TN-XXL
gene expression was introduced into each of the a7-Ric3 and a4b2
cells via lentiviral transduction as described [21] and fluorescence
activated cell sorted (FACS) for high levels of eCFP and Citrine
cp174 fluorescence. Chimaeric receptor DNA of human a7(1-
202)/mouse 5-HT3A was kindly provided by Dr. Steven Sine
(Mayo Clinic, Rochester, MN). The a7/5-HT3A chimaeric
CNiFER was generated by calcium phosphate transfection of
TN-XXL control cells with an a7/5-HT3A gene subcloned into
pcDNA3.1+ containing 5-HT3A conductance-enhancing muta-
tions of R432Q, R436D, and R440A [36]. Stable selection was
achieved using G418 (0.5 mg/ml) to yield a TN-XXL control cell,
as described in [21], containing over-expressed a7/5-HT3A
receptors, which were then selected by FACS as noted above.
Flex Assay on Receptors
Cells were cultured in 10 cm plates with DMEM (Mediatech,
Manassas, VA) supplemented with 10% FBS (Gemini Bio-
Products, West Sacramento, CA; Atlanta Biologicals, Lawrence-
ville, GA) and 1% Glutamine (Invitrogen), and incubated at 37uC
with 10% CO2. Cells were selected at ,70% confluency and
plated the day before using 100 ml volumes per well into black,
transparent flat-bottom, TC treated 96-well plates (Thermo,
Waltham, MA; E&K, Greiner Campbell, CA). Plates were
removed from the incubator the next day and the media was
replaced with 100 ml of artificial cerebral spinal fluid (aCSF)
[containing 121 mM NaCl, 2.4 mM Ca
2+, 1.3 mM Mg
2+,5m M
KCl, 26 mM NaHCO3, 1.2 mM Na2HPO4, 10 mM glucose,
5 mM Hepes Na
+, pH 7.4]. For all assays performed on a7-
nAChR CNiFERs 10 mM of the PAM, PNU-120596 (Tocris,
Ellisville, MO), was prepared in aCSF. In the case of antagonist
measurements, antagonists, at 1.5 times the final desired
concentration, were prepared in aCSF. For non-CNiFER cell
lines, Blue Membrane Potential dye (Molecular Devices, Sunny-
vale, CA) was prepared in aCSF and diluted 2 fold the
recommended dilution. Plates were incubated for at least 30 min
at 37uC and 10% CO2 for any assay that included antagonist, dye,
or PAM modification to the aCSF. Following incubation, plates
were removed and placed into the Molecular Devices FlexStation
III instrument and run at 37uC. Injection rates varied between 27–
48 ml/s, and 50 ml of the specified agonist prepared at 3x final
concentration in the aforementioned aCSF solution was injected
after 30 s of baseline measurement. Reads of both donor eCFP
(485 nm) and acceptor Citrine cp174 (527 nm) emission with
eCFP excitation (436 nm) were made at 3.52 s intervals as shown
in Figure 2a, or for non-CNiFER experiments with blue
membrane dye, 565 nm was read with an excitation of 530 nm,
for 90–120 s depending on the experiment. FRET ratios of the
two wavelengths were plotted as shown in Figure 2b, and the peak
height or initial rate of ion flux for the well was used to determine
EC50 values for the injected agonist, acquired using SoftMax Pro
5.2 (Molecular Devices). All wells were replicated (two or three
times) in the same plate. Mean peak FRET ratios calculated from
Figure 6. 5-HT3A CNiFER: Ondansetron antagonism. A. Competitive blockade of 5-HT elicited responses on 5-HT3A CNiFERs by ondansetron.
The steep Hill coefficient of 2.6 shows the more cooperative nature of the 5-HT3A receptor. The EC50 values for each curve shifted from 220 nM to
1.6 mM, 2.6 mM, and 4.5 mM for 5 nM, 10 nM, 15 nM ondansetron respectively. B. Schild plot of concentration dependent shifts. A slope of -1.360.04
confirmed ondansetron to block competitively.
doi:10.1371/journal.pone.0016519.g006
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tions using Graphpad Prism 4 (Carlsbad, CA). A sigmoidal
concentration-response (variable slope) regression of the mean
peak FRET ratios was fit to generate a concentration-response
curve and obtain an EC50 value.
To measure potencies of competitive antagonists, three
concentration-response curves with different antagonist concen-
trations were compared to a control curve (without antagonist).
Mean FRET responses generated concentration response curves,
and antagonist dependent shifts in EC50 values were used to
calculate dose ratios (DR), as a concentration ratio of EC50’/EC50
for the specified agonist (where EC50’ is in the presence of the
antagonist at the specified concentration). DRs were used to
produce a Schild regression plot for analysis of competitive
antagonism and generate a Ka value. Analysis consisted of potting
Log (DR-1) against –Log [Antagonist]. The Schild Ka value for
competitive antagonists was calculated from the x-intercept at
y=0, as the –Log (Ka) [37,38]. All errors reported are arithmetic
standard deviations unless otherwise noted.
Acknowledgments
The authors would like to thank Dr. Steven Sine for the donation of a7/5-
HT3A cDNA and Wenru Yu for tissue culture expertise.
Author Contributions
Conceived and designed the experiments: JGY AN QTN AM LFS JL DK
PT. Performed the experiments: JGY AN QTN LFS JL. Analyzed the
data: JGY AN TTT JL PT. Contributed reagents/materials/analysis tools:
JL DK PT. Wrote the paper: JGY AN PT. a7/5HT3A-CNiFER cell line
design: JGY. a7, a4b2-CNiFER cell line design: JGY. AN 5-HT3A-
CNiFER cell line design: QTN LFS AM. Assay development and
optimization: AN LFS. Non-CNiFER experimental work: JGY AN JL.
Provided a7, a4b2 cell line: JL. Manuscript edits and review: JGY AN
QTN AM LFS JL DK PWT.
References
1. Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors:
from structure to brain function. Rev Physiol Biochem Pharmacol 147: 1–
46.
2. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, et al. (2008) Initial
phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:
1040–1047.
3. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion
of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits
and synaptic pathology in a mouse model of Alzheimer’s disease. J Neurosci 29:
8805–8815.
4. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, et al. (2007) Impaired
attention is central to the cognitive deficits observed in alpha 7 deficient mice.
Eur Neuropsychopharmacol 17: 145–155.
5. Newhouse PA, Potter A, Levin ED (1997) Nicotinic system involvement in
Alzheimer’s and Parkinson’s diseases. Implications for therapeutics. Drugs Aging
11: 206–228.
6. Warpman U, Nordberg A (1995) Epibatidine and ABT 418 reveal selective
losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6:
2419–2423.
7. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, et al. (2004)
Subunit composition and pharmacology of two classes of striatal presynaptic
nicotinic acetylcholine receptors mediating dopamine release in mice. Mol
Pharmacol 65: 1526–1535.
8. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, et al. (2005) Nicotine
reinforcement and cognition restored by targeted expression of nicotinic
receptors. Nature 436: 103–107.
9. Taly A, Corringer P-J, Guedin D, Lestage P, Changeux J-P (2009) Nicotinic
receptors: allosteric transitions and therapeutic targets in the nervous system.
Nat Rev Drug Discov 8: 733–750.
10. Arneric SP, Holladay M, Williams M (2007) Neuronal nicotinic receptors: a
perspective on two decades of drug discovery research. Biochem Pharmacol 74:
1092–1101.
11. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R (2008) High-throughput
electrophysiology: an emerging paradigm for ion-channel screening and
physiology. Nat Rev Drug Discov 7: 358–368.
12. Sidach SS, Fedorov NB, Lippiello PM, Bencherif M (2009) Development and
optimization of a high-throughput electrophysiology assay for neuronal
alpha4beta2 nicotinic receptors. J Neurosci Methods 182: 17–24.
13. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, et al. (2007) In vitro
screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74:
1172–1181.
14. Fitch RW, Xiao Y, Kellar KJ, Daly JW (2003) Membrane potential
fluorescence: a rapid and highly sensitive assay for nicotinic receptor channel
function. Proc Natl Acad Sci U S A 100: 4909–4914.
15. Baubet V, Le Mouellic H, Campbell AK, Lucas-Meunier E, Fossier P, et al.
(2000) Chimeric green fluorescent protein-aequorin as bioluminescent Ca2+
reporters at the single-cell level. Proc Natl Acad Sci U S A 97: 7260–7265.
16. Drobac E, Tricoire L, Chaffotte AF, Guiot E, Lambolez B (2010) Calcium
imaging in single neurons from brain slices using bioluminescent reporters.
J Neurosci Res 88: 695–711.
17. Kleinfeld D, Griesbeck O (2005) From art to engineering? The rise of in vivo
mammalian electrophysiology via genetically targeted labeling and nonlinear
imaging. PLoS Biol 3: e355.
18. Mank M, Griesbeck O (2008) Genetically encoded calcium indicators. Chem
Rev 108: 1550–1564.
19. Miyawaki A (2005) Innovations in the imaging of brain functions using
fluorescent proteins. Neuron 48: 189–199.
20. Mank M, Santos AF, Direnberger S, Mrsic-Flogel TD, Hofer SB, et al. (2008) A
genetically encoded calcium indicator for chronic in vivo two-photon imaging.
Nature Methods 5: 805–811.
21. Nguyen Q-T, Schroeder LF, Mank M, Muller A, Taylor P, et al. (2009) An in
vivo biosensor for neurotransmitter release and in situ receptor activity. Nature
Neuroscience 13: 127–132.
22. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, et al. (1993)
Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and
channel specificities. Nature 366: 479–483.
23. Craig P, Bose S, Zwart R, Beattie R, Folly E, et al. (2004) Stable expression and
characterisation of a human a7 nicotinic subunit chimera: a tool for functional
high-throughput screening. Eur J Pharmacol 502: 31–40.
24. Rayes D, Spitzmaul G, Sine SM, Bouzat C (2005) Single-channel kinetic analysis
of chimeric alpha7-5HT3A receptors. Mol Pharmacol 68: 1475–1483.
25. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary
structure and functional expression of the 5HT3 receptor, a serotonin-gated ion
channel. Science 254: 432–437.
26. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, et al. (1999) The 5-
HT3B subunit is a major determinant of serotonin-receptor function. Nature
397: 359–363.
27. Papke R, Schiff H, Jack B, Horenstein N (2005) Molecular dissection of
tropisetron, an a7 nicotinic acetylcholine receptor-selective partial agonist.
Neuroscience Letters 378: 140–144.
28. Bouzat C, Bartos M, Corradi J, Sine SM (2008) The interface between
extracellular and transmembrane domains of homomeric Cys-loop receptors
governs open-channel lifetime and rate of desensitization. J Neurosci 28:
7808–7819.
29. Roncarati R, Seredenina T, Jow B, Jow F, Papini S, et al. (2008) Functional
properties of a7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a
stable recombinant CHO-K1 cell line. ASSAY Drug Dev Technol 6: 181–193.
30. Bertrand D, Gopalakrishnan M (2007) Allosteric modulation of nicotinic
acetylcholine receptors. Biochem Pharmacol 74: 1155–1163.
31. Young GT, Zwart R, Walker AS, Sher E, Millar NS (2008) Potentiation of 7
nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl
Acad Sci U S A 105: 14686–14691.
32. Sine S, Taylor P (1979) Functional consequences of agonist-mediated state
transitions in the cholinergic receptor. Studies in cultured muscle cells. J Biol
Chem 254: 3315–3325.
33. Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, et al.
(1999) Characterisation of the binding of [3H]methyllycaconitine: a new
radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.
Neuropharmacol 38: 679–690.
34. Sine SM, Taylor P (1981) Relationship between reversible antagonist occupancy
and the functional capacity of the acetylcholine receptor. J Biol Chem 256:
6692–6699.
35. Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a
pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine
receptors. Mol Pharmacol 68: 1839–1851.
36. Kelley SP, Dunlop JI, Kirkness EF, Lambert JJ, Peters JA (2003) A cytoplasmic
region determines single-channel conductance in 5-HT3 receptors. Nature 424:
321–324.
37. Taylor P, Insel PA (1990) Molecular basis of pharmacologic selectivity. Chapter
1. In: Pratt WB, Taylor P, eds. Principles of drug action: the basis of
pharmacology 3rd Ed 3rd ed.. New York: Churchill Livingstone. pp 1–102.
38. Wyllie DJA, Chen PE (2009) Taking the time to study competitive antagonism.
Br J Pharmacol 150: 541–551.
39. Chavez-Noriega LE, Gillespie A, Stauderman KA, Crona JH, Claeps BO, et al.
(2000) Characterization of the recombinant human neuronal nicotinic
Ligand-Gated Ion Channel Sensor Cell
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16519acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in
HEK293 cells. Neuropharmacol 39: 2543–2560.
40. Kuryatov A, Onksen J, Lindstrom J (2008) Roles of accessory subunits in
alpha4beta2(*) nicotinic receptors. Mol Pharmacol 74: 132–143.
41. Rizzi JP, Nagel AA, Rosen T, McLean S, Seeger T (1990) An initial three-
component pharmacophore for specific serotonin-3 receptor ligands. J Med
Chem 33: 2721–2725.
42. Rosen T, Nagel AA, Rizzi JP, Ives JL, Daffeh JB, et al. (1990) Thiazole as a
carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor
antagonists. J Med Chem 33: 2715–2720.
Ligand-Gated Ion Channel Sensor Cell
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16519